Rocket Pharma H1 2024 net loss $131.7M; KRESLADI review ongoing, cash into 2026

ROCKET PHARMACEUTICALS, INC.

2024-Q2 EPS reported -$1.40

Net loss of $131.7M ($1.40/sh) for H1 2024 vs $124.0M ($1.55/sh) for H1 2023.
Cash, equivalents & investments $278.8M; runway expected into 2026.
FDA requested additional CMC info for KRESLADI (LAD-I); working to support approval.
Phase 2 pivotal enrollment ongoing for RP-A501 (Danon) and RP-L301 (PKD) initiated.
EC granted orphan medicinal product designation for RP-A601 (PKP2-ACM); Phase 1 enrolling.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.